Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Issue 8 (3rd August 2018)

• Record Type: Journal Article
• Authors: Giulino-Roth, Lisa; O'Donohue, Tara; Chen, Zhengming; Trippett, Tanya M.; Klein, Elizabeth; Kernan, Nancy A.; Kobos, Rachel; Prockop, Susan E.; Scaradavou, Andromachi; Shukla, Neerav; Steinherz, Peter G.; Moskowitz, Alison J.; Moskowitz, Craig H.; Boulad, Farid
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 8(2018)
• Page Start: 1861
• Page End: 1870
• Publication Date: 2018-08-03
• Subjects: Clinical results -- marrow and stem cell transplantation -- lymphoma and Hodgkin disease -- neoplasia -- prognostication; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1403601
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 ( p = .0015), 0.18 ( p = .0039), and 0.17 ( p = .0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients ( n = 22) and a lower score was associated with improved OS (HR 0.29, p = .0352) and a trend toward improved EFS (HR 0.38, p = .0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.